Matridx
Latest round
- Series B
Last raised
- Jan 2021
Total raised
- $31M
Investors
- 4
About Matridx
Established in 2019 and based in Hangzhou, China, Matridx is an innovative technology enterprise that focuses on the molecular diagnosis of infectious diseases. The company has acquired more than 100 patents. It has cooperated with Peking Union Medical College Hospital, Huashan Hospital of the Shanghai FuDan University, and Guangzhou Institute of Respiratory Health. In 2023, Matridx launched Targeted NGS (tNGS) for Pathogenic Microorganisms. In July 2024, the firm closed a strategic investment. The company provides the diagnosis of infectious diseases solutions for patients, developed gene editing (CRISPR/Cas) and high-throughput sequencing (NGS) as the technology platforms, and adopted the technology of genetic testing, big data analysis, and artificial intelligence. Specific products and services include Pathogen Macro Gene Banker, mNGS Assay Kit, microbial mMGS solution, and SARS-CoV -2 nucleic acid detecting solution. It also developed an automated Library prep instrument. The company’s revenue is generated by providing molecular diagnostic solutions for infectious diseases.
Who invested in Matridx
4 investors across 2 rounds
See all investors in Matridx
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Matridx
Who invested in Matridx?
Matridx has 4 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Matridx raised?
Matridx has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Matridx last raise money?
Matridx's most recent round on record is a Series B, in Jan 2021.
What does Matridx do?
Established in 2019 and based in Hangzhou, China, Matridx is an innovative technology enterprise that focuses on the molecular diagnosis of infectious diseases.
Where is Matridx headquartered?
Matridx is headquartered in Hangzhou, China.
Which VCs invest in companies like Matridx?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Matridx's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Matridx? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.